Last reviewed · How we verify
P-CAB 50
At a glance
| Generic name | P-CAB 50 |
|---|---|
| Sponsor | Duk-Woo Park, MD |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy (PHASE4)
- Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori） (PHASE4)
- Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia (PHASE4)
- Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole (PHASE4)
- Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole (PHASE4)
- Cardiac and Endothelial Function Response to Early Exercise Training After Coronary Artery Bypass Surgery (NA)
- Evaluation of the Effect of 10% Lidocaine Spray Undergoing Coronary Artery Bypass Graft Operation (PHASE4)
- Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |